OpenAI
OpenAI acquires Orchestra Bio to support life sciences R&D
OpenAI is acquiring Orchestra Bio in an effort to bring AI-powered operations to life sciences research and development. The acquisition's stated aim is to help teams in the biopharmaceutical sector accelerate drug development and advance the development of new treatments.
Source published: Brief prepared:
What to know
- 01
OpenAI is acquiring Orchestra Bio to introduce AI-powered operations into life sciences R&D.
- 02
The goal is to help biopharma teams develop drugs faster and advance new treatments.
Why it matters
The acquisition reflects OpenAI's aim to apply AI to life sciences R&D operations in support of drug and treatment development.
Original sourceRead the source · OpenAIopenai.com
AI-assisted brief. Read the source for full details. Editorial & sourcing policy
